Dyadic International Inc, DE Dossier
Qualitative Analysis
Business overview
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology platform company headquartered in Jupiter, Florida. The company focuses on the development, manufacturing, and commercialization of proteins and enzymes using its proprietary gene expression systems. Its core technologies revolve around the highly productive, scalable Thermothelomyces heterothallica fungal platform, historically known as the C1 Protein Production Platform. This platform is designed to produce biologic products, vaccines, and therapeutics for human and animal health at a lower cost and higher scale than legacy systems. Additionally, Dyadic utilizes its Dapibus™ platform to address the growing global demand for non-animal-derived proteins and enzymes in non-pharmaceutical markets, including food, nutrition, wellness, and bio-industrial applications.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivot from a development-stage platform company to a commercially focused biotechnology firm delivering applied protein and enzyme solutions under the d/b/a Dyadic Applied BioSolutions.
Expected impact: Aims to build a commercial pipeline in non-pharmaceutical markets (life sciences, food & nutrition, bio-industrial) to generate recurring product sales and profit-sharing revenues.
Non-exclusive license agreement with ERS Genomics for the use of CRISPR/Cas9 gene editing technology.
Expected impact: Supports strain engineering and production optimization across microbial expression platforms to accelerate development timelines.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Leverages Dyadic's microbial protein production technologies and Fermbox's fermentation and scale-up capabilities to accelerate commercialization of animal-free proteins and enzymes.
Terms: Co-development and commercialization of additional animal-free proteins and enzymes across life sciences, food and nutrition, and bio-industrial markets.
Development of recombinant bovine alpha-lactalbumin for global nutrition markets using Dyadic's Dapibus™ expression system.
Terms: BRIG BIO funds development activities; Dyadic is eligible to receive development funding, milestone payments, and revenue participation tied to future commercial sales.
Collaboration to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses (including Andes virus) using Dyadic's proprietary C1 platform.
Terms: Pursued through grants, sponsored research, and strategic collaborations to validate the C1 platform in a capital-efficient manner.